Loading
institutionsInstitution
INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia
Valencia's university hospital and research institute, base of former ESMO president Andrés Cervantes and a leading gastrointestinal and breast oncology group.
Also called: INCLIVAHospital Clínico de Valencia
Overview
INCLIVA is the health research institute of the Hospital Clínico Universitario de Valencia and the University of Valencia. Its medical oncology department under Andrés Cervantes, ESMO president in 2023-2024, is a European reference for colorectal and gastric cancer trials and for circulating tumour DNA studies in localised colorectal cancer, and Ana Lluch's breast cancer group helped found the GEICAM and SOLTI cooperative groups. Research lines include tumour microenvironment, precision oncology and cancer genomics, and the hospital runs a phase 1 unit and hereditary cancer clinic. It cooperates with La Fe across the Valencian cancer network.
Location
Valencia, ES
Type
hospital · Universitat de València
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#178 · 30 points (0 Newsweek + 0 NCI + 30 from 15 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to Hospital Clínico Universitario de Valencia, including child institutions. 377 works · 3,050 citations · 66% open access · 15% clinical trials · 1% reviews.
Oncology works per year
642022
832023
842024
802025
662026
Most works
- Rafael Hernani40 works
- Begoña Bermejo37 works
- Mi Kwon32 works
- Lucía López‐Corral30 works
- Mariana Bastos‐Oreiro26 works
- Gloria Iacoboni25 works
- Ana Benzaquén23 works
- Andrés Cervantes23 works
- Juan Luis Reguera21 works
- Pere Barba20 works
Most cited
- Gastrointestinal oncology trials
- ctDNA in colorectal cancer
- Breast cancer (GEICAM, SOLTI)
- Phase 1 unit
Álvaro Bonet Pla
Representative of INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Álvaro Bonet Pla represents INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.
Andrés Cervantes
Professor of Medicine, University of Valencia; Head of Medical Oncology, INCLIVA; ESMO President 2023-2024
Gastrointestinal oncologyColorectal cancerGuidelines
Andrés Cervantes is a gastrointestinal oncologist and was ESMO President for 2023-2024.
Similar pages
- IdeaTake the blood test, and give the drug, at the right time of day
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- Key paperPlasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- TreatmentOncodetect
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- Key paperCirculating tumor DNA as a clinical test in resected pancreatic cancer
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaBreak the neutrophil DNA nets that catch tumour cells after surgery
Shares Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Pancreatic ductal adenocarcinoma.
- Key paperc-TRAK TN analysis: tissue-free versus tumour-informed ctDNA assays for residual disease in early triple-negative breast cancer
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- Key paperCirculating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaCirculating tumour cell clearance as the phase 2 gate for anti-metastatic drugs
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).